Your activity: 1952 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: [email protected]

Trace metals: Pediatric drug information

Trace metals: Pediatric drug information
(For additional information see "Trace metals: Drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Multrys;
  • Tralement
Brand Names: Canada
  • Micro+ 4 Regular;
  • Micro+ 6 Concentrate
Therapeutic Category
  • Mineral, Parenteral;
  • Trace Element, Multiple, Neonatal;
  • Trace Element, Parenteral
Dosing: Neonatal

Parenteral nutrition; maintenance requirements: IV: As an additive to parenteral nutrition solution; see individual agents (chromium, copper, manganese, and zinc) (ASPEN [Vanek 2012])

Dosing: Pediatric

Parenteral nutrition; maintenance requirements: Infants, Children, and Adolescents: IV: As an additive to parenteral nutrition solution; see individual agents (chromium, copper, manganese, and zinc) (ASPEN [Vanek 2012])

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; some compenents may require dosing adjustment; see individual agents

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; some components may require dosing adjustment; see individual agents

Dosing: Adult

(For additional information see "Trace metals: Drug information")

Parenteral nutrition, maintenance requirements: Note: Does not contain chromium. Use in patients who require supplementation with all 4 of the individual trace elements (zinc, copper, manganese, and selenium).

IV: 1 mL per day added to parenteral nutrition (1 mL provides the following: zinc 3 mg, copper 0.3 mg, manganese 55 mcg, selenium 60 mcg).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous [preservative free]:

Tralement: Copper 300 mcg, manganese 55 mcg, selenium 60 mcg, and zinc 3,000 mcg per 1 mL (1 mL)

Multrys (Pediatric product): Copper 60 mcg, manganese 3 mcg, selenium 6 mcg, and zinc 1,000 mcg per 1 mL (1 mL)

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Micro+ 4 Regular: Chromium 4 mcg, copper 400 mcg, manganese 100 mcg, and zinc 1,000 mcg per 1 mL (5 mL)

Micro+ 6 Concentrate: Chromium 10 mcg, copper 300 mcg, iodide 75 mcg, manganese 55 mcg, selenium 60 mcg, and zinc 5,000 mcg per 1 mL (10 mL)

Generic: Chromium 4 mcg, copper 400 mcg, manganese 100 mcg, and zinc 1,000 mcg per 1 mL ([DSC])

Administration: Pediatric

Parenteral: Must be diluted prior to use and infused as component of parenteral nutrition or parenteral solutions

Administration: Adult

For IV use only. Must be diluted prior to use and infused as component of parenteral nutrition or parenteral solutions. Do not administer undiluted solutions by direct injection into a peripheral vein.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Store admixed solution at 2°C to 8°C (36°F to 46°F).

Use

Prevention and treatment of trace metal deficiencies (FDA approved in all ages)

Contraindications

Hypersensitivity to zinc, copper, or any component of the formulation; administration of undiluted solutions by direct injection into a peripheral vein.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reactions: Hypersensitivity reactions (eg, angioedema, dyspnea, pruritus, rash, urticaria) have been reported in patients exposed to copper or zinc containing products (eg, zinc-containing insulin or copper-containing intrauterine devices). Discontinue treatment and institute appropriate treatment if hypersensitivity occurs.

Disease-related concerns:

• Hepatic impairment: Copper and manganese may accumulate in severe hepatic impairment and/or biliary obstruction; consider reduction in dosage or deletion of copper and manganese in patients with severe hepatic impairment or biliary obstruction.

• Renal impairment: Use with caution in patients with renal impairment; metals may accumulate in renal failure.

Other warnings/precautions:

• Aluminum toxicity: Contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or in patients with renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses.

• Manganese toxicity: Basal ganglia accumulation (detected on MRI) and clinical symptoms (eg, neuropsychiatric, seizures, parkinsonian-like tremor, dysarthria, mask-face, halting gate, dystonic movements) of manganese toxicity have been reported in adult and pediatric patients, including patients receiving manganese at or below recommended doses and with normal blood manganese levels. Risk may be increased in patients receiving higher than recommended doses and with cholestatic liver disease. Symptoms and MRI findings generally improve over weeks to months following discontinuation of manganese but may not completely resolve. Monitor manganese blood levels and for neurologic toxicity in patients receiving manganese long-term as a component of parenteral nutrition therapy. If manganese toxicity is suspected, temporarily discontinue and further evaluate.

• Overdose potential: Multiple trace metal solutions present a risk of overdosage when the need for one trace element is appreciably higher than for others in the formulation; utilization of individual trace metal solutions may be needed (especially chromium since product does not contain chromium).

Dietary Considerations

ASPEN 2020 :

Copper: 0.3 to 0.5 mg/day.

Manganese: 55 mcg/day.

Selenium: 60 to 100 mcg/day.

Zinc: 3 to 5 mg/day.

Pregnancy Considerations

Refer to individual elements for requirements in pregnancy.

Mechanism of Action

Copper: Cofactor for serum ceruloplasmin, an oxidase necessary for proper formation of the iron carrier protein, transferrin; also helps maintain normal rates of red and white blood cell formation and prevents development of leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferrin formation and secondary iron deficiency.

Manganese: Activator for enzymes such as polysaccharide polymerase, liver arginase, cholinesterase and pyruvate carboxylase and prevents development of nausea and vomiting, weight loss, dermatitis, and changes in growth and hair color.

Selenium: Protects cell components from oxidative damage due to peroxides produced in cellular metabolism and prevents development of muscle pain and tenderness.

Zinc: Facilitates wound healing, helps maintain normal growth rates, normal skin hydration and senses of taste and smell and prevents development of parakeratosis, hypogeusia, anorexia, dysosmia, geophagia, hypogonadism, growth retardation and hepatosplenomegaly.

Pharmacokinetics (Adult data unless noted)

Excretion:

Copper: Urine, bile.

Manganese: Bile.

Selenium: Urine, feces.

Zinc: Urine, feces.

Pricing: US

Solution (Multitrace-4 Neonatal Intravenous)

100-25-1500 mcg/mL (per mL): $6.95

Solution (Multitrace-4 Pediatric Intravenous)

1-100-25-1000 mcg/mL (per mL): $4.86

Solution (Trace Elements 4/Pediatric Intravenous)

1-100-30-500 mcg/mL (per mL): $0.88

Solution (Tralement Intravenous)

300-55-60-3000 mcg/mL (per mL): $25.80

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

REFERENCES

  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. http://www.nutritioncare.org/PNDosing. Updated November 17, 2020.
  3. Corkins MR, Martin VA, Szeszycki EE. Copper levels in cholestatic infants on parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013;37(1):92-96. [PubMed 22610978]
  4. Dahlstrom KA, Ament ME, Medhin MG, et al, "Serum Trace Elements in Children Receiving Long-Term Parenteral Nutrition," J Pediatr, 1986, 109(4):625-30. [PubMed 3093658]
  5. Department Health and Human Services, Food Drug Administration, "Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition," Federal Register, 2000, 65(17):4103-11.
  6. Fell JM, Reynolds AP, Meadows N, et al, "Manganese Toxicity in Children Receiving Long-Term Parenteral Nutrition," Lancet, 1996, 347(9010):1218-21. [PubMed 8622451]
  7. Finch CW. Review of trace mineral requirements for preterm infants: what are the current recommendations for clinical practice? Nutr Clin Pract. 2015;30(1):44-58. [PubMed 25527182]
  8. Greene HL, Hambridge KM, Schanler R, et al, "Guidelines for the Use of Vitamins, Trace Elements, Calcium, Magnesium and Phosphorus in Infants and Children Receiving Total Parenteral Nutrition: Report of the Subcommittee on Pediatric Nutrient Requirements From the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition," Am J Clin Nutr, 1988, 48(5):1324-42. [PubMed 3142247 ]
  9. Koletzko B, Goulet O, Hunt J, et al. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr. 2005;41 Suppl 2:S1-87. [PubMed 16254497]
  10. Litov RE and Combs GF Jr, "Selenium in Pediatric Nutrition," Pediatrics, 1991, 87(3):339-51. [PubMed 2000274]
  11. Mirtallo J, Canada T, Johnson D, et al; Task Force for the Revision of Safe Practices for Parenteral Nutrition. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28(6):S39-S70. doi:10.1177/0148607104028006s39 [PubMed 15568296]
  12. Multrys (trace elements injection 4, USP) [prescribing information]. Shirley, NY: American Regent, Inc; June 2021.
  13. Selenious acid injection [prescribing information]. Shirley, NY: American Regent Inc.; November 2015.
  14. Tralement (trace elements injection 4) [prescribing information]. Shirley, NY: American Regent, Inc; July 2020.
  15. Vanek VW, Borum P, Buchman A, et al. A call to action to bring safer parenteral micronutrient products to the U.S. market. Nutr Clin Pract. 2015;30(4):559-569. [PubMed 26113560]
  16. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-491. [PubMed 22730042]
Topic 12853 Version 115.0